Nuvilex Inc. (NASDAQ:PMCB) Short Interest Down 61.7% in August

Nuvilex Inc. (NASDAQ:PMCB) was the recipient of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 79,793 shares, a drop of 61.7% from the August 15th total of 208,161 shares. Based on an average trading volume of 91,412 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.8% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Nuvilex Trading Up 1.8%

Shares of PMCB stock traded up $0.01 on Friday, reaching $0.45. The company had a trading volume of 48,490 shares, compared to its average volume of 92,904. The stock has a market cap of $4.84 million, a PE ratio of -0.15 and a beta of 0.66. The company has a 50-day moving average of $0.57 and a 200-day moving average of $0.68. Nuvilex has a 12 month low of $0.43 and a 12 month high of $1.51.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.